Abstract
SBP is a serious and costly cirrhosis complication, with ∼50% of cases requiring ICU admission. Due to its demonstrated efficacy in critical care settings, albumin is recommended by the American Association for the Study of Liver Diseases as an adjuvant to antibiotics for the management of SBP. We examined the relationship between early albumin infusion and ICU cost in a subgroup of cirrhotic patients who developed SBP during hospitalization.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have